Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group

Publication date: Available online 27 July 2019Source: Journal of Geriatric OncologyAuthor(s): Sotirios G. Papageorgiou, Christos K. Kontos, Ioannis Kotsianidis, Paraskevi Karousi, Argyris Symeonidis, Athanasios Galanopoulos, Anthi Bouchla, Eleftheria Hatzimichael, Panagiotis Repousis, Panagiotis Zikos, Nora-Athina Viniou, Elias Poulakidas, Theodoros P. Vassilakopoulos, Panagiotis Diamantopoulos, Despoina Mparmparousi, Eleni Bouronikou, Helen Papadaki, Panayiotis Panayiotidis, Vasiliki Pappa
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

In this study, we first tested the role of Peg-Dox in the killing of myeloid cell lines and of primary myeloid leukemia cells. Then, a Peg-Dox-based protocol was used to treat patients with myeloid neoplasms. The results showed that the Peg-Dox and Peg-Dox-based protocols had a similar killing ability in myeloid cell lines and in primary myeloid leukemia cells compared to that of conventional doxorubicin. The complete remission rate was 87.5% and 100% for patients with refractory/relapsed acute myeloid leukemia and myelodysplastic syndrome with excess blasts, respectively, after treatment with Peg-Dox. All patients develop...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Reports Source Type: research
This article reviews the mechanism of action, pharmacology, safety profile and clinical efficacy of subcutaneous guadecitabine, a second generation DNA methylation inhibitor in development for the treatment of AML and MDS. Expert Opinion: Although guadecitabine did not yield improved complete remission (CR) rates and OS compared to the control arm in patients with treatment-naïve AML who were ineligible for intensive chemotherapy, subgroup analysis in patients who received ≥ 4 cycles of therapy demonstrated superior outcomes in favor of guadecitabine. Given its stability, ease of administration, safety profile and ...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
CONCLUSIONS: Despite the wide use of EPO alfa in the treatment of anaemia in patients with MDS, the median response duration is approximately only 24 months. Our data provide encouraging results concerning the benefits of using EPO alfa for the improvement of the quality of life, as patients treated with EPO showed higher overall survival, event-free survival rates and longer response durations than have been previously described in the literature.
Source: Clinics - Category: General Medicine Source Type: research
Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome Intervention:   Biological: ASP7517 Sponsor:   Astellas Pharma Global Development, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ier S Abstract Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine. PRIMA-1Met (APR-246, APR) is a methylated derivative of PRIMA-1, which induces apoptosis in human tumor cells through restoration of the transcriptional transactivation function of mutant p53. We show here that low doses of APR on its own or in combination with 5-azacitidine reactivate the p53 pathway and induce an apoptosis program. Functionally, we demonstrate that...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Allogeneic hematopoietic cell transplantation (alloHCT) offers the potential for cure for many hematologic malignancies but is associated with high risk of morbidity and mortality, and thus has been historically reserved for younger patients. Nevertheless, older adults disproportionately suffer from hematologic malignancies that have indications for alloHCT, such as acute myeloid leukemia and myelodysplastic syndrome, which have median ages at diagnosis of 68 and 77 years, respectively [1]. With improved supportive care and the development of reduced intensity conditioning regimens, the number of alloHCT for older adults h...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
ang Chang The unsatisfactory real-world efficacy of the hypomethylating agent azacitidine in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) has prompted us to investigate the hematological adverse events and host variables that may compromise the use of this epigenetic drug. Using the zebrafish, we found that azacitidine destroyed their myeloid precursors and impaired myeloid function by inhibiting antigen processing, allogeneic response and phagocytic activity, resulting in increased susceptibility to infection even by the normal flora E. coli. In addition, iron overload, a MDS-associated...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Relapse of the underlying disease is the most frequent cause of treatment failure after allogeneic HCT for hematologic malignancies [1]. Non-relapse mortality (NRM) accounts for the bulk of the remainder of deaths (20-30%) [2 –5]. One of the strategies to reduce relapse risk is to intensify the pre-transplant conditioning regimen. Several studies have demonstrated that increasing the intensity of the conditioning regimen can reduce relapse risk [6–9]. Indeed, a prospective randomized trial of myeloablative (MAC) vers us reduced intensity conditioning (RIC) for adults with acute myeloid leukemia (AML) and myelod...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Growth factor independence 1 (GFI1) is known as a DNA binding zinc finger protein which can mediate transcriptional repression mainly by recruiting histone-modifying enzymes to its target genes. GFI1 plays important roles in hematopoiesis, in particular in regulating the function of hematopoietic stem- and precursor cells and the differentiation along myeloid and lymphoid lineages. In recent years, a number of publications provided evidence that GFI1 is involved in the pathogenesis of both acute myeloid leukemia (AML) and its proposed precursor stage, the myelodysplastic syndrome (MDS), and possibly also in the progression...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS.—: Myelodysplastic syndrome and acute myeloid leukemia in Down syndrome display features that allow discrimination from standard cases of disease. These distinctions are important for treatment decisions, and for understanding disease pathogenesis. We propose specific diagnostic criteria for Down syndrome-related subtypes of acute myeloid leukemia and myelodysplastic syndrome. PMID: 31429606 [PubMed - as supplied by publisher]
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Tags: Arch Pathol Lab Med Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Geriatrics | Greece Health | Leukemia | Myelodysplastic Syndrome | Study